Journal
HEALTH CARE MANAGEMENT SCIENCE
Volume 25, Issue 3, Pages 363-388Publisher
SPRINGER
DOI: 10.1007/s10729-022-09596-2
Keywords
OR in medicine; Risk reduction; Markov decision process (MDP); Breast cancer
Categories
Ask authors/readers for more resources
Each woman has a different risk of developing breast cancer, and existing national clinical guidelines have limited use of personal risk when proposing risk reduction strategies. A study suggests that mastectomy may be the optimal choice for borderline high-risk women aged 22 to 38, contrary to current recommendations. Additionally, exemestane may be a plausible and even the best option for high-risk postmenopausal women, contradicting the National Comprehensive Cancer Network recommendations.
Depending on personal and hereditary factors, each woman has a different risk of developing breast cancer, one of the leading causes of death for women. For women with a high-risk of breast cancer, their risk can be reduced by two main therapeutic approaches: 1) preventive treatments such as hormonal therapies (i.e., tamoxifen, raloxifene, exemestane); or 2) a risk reduction surgery (i.e., mastectomy). Existing national clinical guidelines either fail to incorporate or have limited use of the personal risk of developing breast cancer in their proposed risk reduction strategies. As a result, they do not provide enough resolution on the benefit-risk trade-off of an intervention policy as personal risk changes. In addressing this problem, we develop a discrete-time, finite-horizon Markov decision process (MDP) model with the objective of maximizing the patient's total expected quality-adjusted life years. We find several useful insights some of which contradict the existing national breast cancer risk reduction recommendations. For example, we find that mastectomy is the optimal choice for the border-line high-risk women who are between ages 22 and 38. Additionally, in contrast to the National Comprehensive Cancer Network recommendations, we find that exemestane is a plausible, in fact, the best, option for high-risk postmenopausal women.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available